Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Vote in favor of your #1 Sort of Convenience for a Family - 2NASA set for first crewed moon return in over half a century
- 3Where should we send a real 'Hail Mary' spacecraft? A new study has the answers
- 46 Top Computer game Control center
- 5Italy now recognizes the crime of femicide and punishes it with life in prison
- Vote In favor of Your Favored Distributed computing Administration
- The most effective method to Pick the Right Material Organization: Fundamental Tips
- The Best Traditional Music Arrangers in History
- Energy agency chief warns of 'black April' for oil supplies
- Yasser Abu Shabab's killing raises questions about Israel's militia strategy in Gaza
- NASA satellite gazes into Medusa Pool | Space photo of the day for Dec. 24, 2025
- Recalled Super Greens diet supplement powder sickens 45 with salmonella
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- FDA official discusses potential link between COVID-19 vaccines and pediatric deaths
